ARTICLE | Company News

J&J ends deal for Macrogenics' duvortuxizumab

September 8, 2017 8:41 PM UTC

MacroGenics Inc. (NASDAQ:MGNX) said the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) terminated its license to duvortuxizumab (MGD011), a bispecific antibody against CD19 and CD3. MacroGenics said the termination will not affect a separate deal granting Janssen exclusive, worldwide rights to cancer candidate MGD015 (JNJ-9383), a bispecific antibody targeting CD3 and an undisclosed antigen expressed in lung and blood cancers that is slated to enter clinical testing next year. Both antibodies were developed using MacroGenics' Dual-Affinity Re-Targeting (DART) technology (see BioCentury, May 23, 2016).

MacroGenics said enrollment in a Phase I trial of duvortuxizumab to treat B cell malignancies will be discontinued and that the company is unlikely to continue development of the candidate at this time. The company added that “recent advances” in the treatment of B cell malignancies have made the opportunity for further development of duvortuxizumab “less attractive.”...

BCIQ Target Profiles